Established in 2017, Elpis is a pre-clinical stage biopharmaceutical company. Our vision is to become a leading biotech company by developing innovative biological and cellular therapeutics for difficult-to-treat cancers. We have built two core technology platforms: the mADsTM platform to discover fully human therapeutic antibodies and the mSCAFoldTM platform to develop novel mechanism-driven protein therapeutics. Elpis is advancing a rich pipeline composed of immuno-modulators, dual targeting tandem CAR-Ts and novel bispecific antibodies. Those modalities could potentiate synergistic effects in augmenting immune activation through combinational therapy. Our leading programs include an immunomodulator for solid tumors (from mSCAFoldTM ) and a dual targeting CAR-T for hematologic malignancies (from mADsTM). Both programs are projected to enter human clinical studies in early 2021.
Our team includes the well-respected biologics drug discovery & development experts with extensive experience and track records in advancing biotherapeutic candidates into clinical and commercial stage.